[Skip to Navigation]
Sign In
Editorial
June 24, 2021

Adjuvant Zoledronate Therapy for Women With Breast Cancer—Effective Treatment or Fool’s Gold?

Author Affiliations
  • 1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
JAMA Oncol. 2021;7(8):1121-1123. doi:10.1001/jamaoncol.2021.1516

In this issue of JAMA Oncology, Friedl and colleagues1 report results of the SUCCESS-A trial in which 2987 women were randomized to receive zoledronate either for 5 years (4 mg intravenously every 3 months for 2 years, then every 6 months for 3 years) or for 2 years (4 mg intravenously every 3 months). Eligible women had invasive breast cancer at high risk of recurrence: either node-positive or node-negative with a tumor size greater than 2 cm, histological grade 3, negative hormone-receptor status, or in women 35 years or younger. Both premenopausal and postmenopausal women participated; they received adjuvant chemotherapy, and zoledronate treatment was started after its completion. Women with hormone receptor–positive cancer received endocrine treatment for 5 years. Analysis of SUCCESS-A at a median of 5 years after initiation of zoledronate showed no significant difference in its primary end point of disease-free survival (DFS) for women receiving 5-year or 2-year adjuvant zoledronate (hazard ratio [HR], 0.97; 95% CI, 0.76-1.25; P = .83). There was also no statistically significant difference in overall survival (OS), distant disease-free survival, and bone recurrence–free survival. There were no discernable trends for subgroups defined by menopausal or hormone-receptor status.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×